Loading clinical trials...
Loading clinical trials...
Discover 14,325 clinical trials near Salt Lake City, Utah. Find research studies in your area.
Showing 13581-13600 of 14,325 trials
NCT00342212
Background: * Good measures of physical activity are needed for studies correlating physical activity and the risk of developing certain diseases. * In preparation for use in a study of diseases and risk factors in Hispanic populations, NCI is evaluating a new model accelerometer to measure physical activity. An accelerometer is a small device worn on a belt at the waist that measures and records movement, capturing movement intensity and duration and associating it with clock-time. * The new accelerometer (ActiGraph GTIM) uses a different type of motion detector from that used in the previous model (ActiGraph 7164). Objective: To evaluate and compare the ActiGraph GTIM with the ActiGraph 7164 by collecting physical activity data using both models. Eligibility: Men and women 18-74 years of age. Design: Study participants wear both model accelerometers while they walk or jog around a track at several self-selected paces. Data from the two devices are compared.
NCT00311701
This retrospective study conducted in Canada and the US involves a chart review to assess the safety of oseltamivir (Tamiflu®) compared to alternate antiviral therapy, amantidine or rimantidine, administered to children less than 12 months of age with diagnosed or suspected influenza. The objectives are to describe the frequency of neurological and all other adverse events possibly related to administration of these antivirals in these infants. Investigators will also compare frequency of adverse events at various doses of oseltamivir in these children. Critical endpoints to be collected include frequency and severity of adverse events, particularly those relating to central nervous system complications. A sub-investigator will travel to each of the participating sites to collect data related to each infant's health prior to becoming ill, health status at time of influenza diagnosis, dosing regimen, reported neurological events post-dosing, and all reported adverse events post-dosing.